search
Back to results

The Role of Ketamine and Dexmedetomidine in Opioid-Sparing Analgesia

Primary Purpose

Ketamine-Induced Mood Disorder

Status
Completed
Phase
Not Applicable
Locations
Egypt
Study Type
Interventional
Intervention
Ketamine
Sponsored by
Fayoum University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Ketamine-Induced Mood Disorder focused on measuring ketamine, dexmedetomidine, Analgesia, Cardiac Surgery, Sedation

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Age 18 - 65 years
  • Ejection fraction (EF) > 35%
  • Elective isolated CABG
  • Valve surgery, Atrial septal defect (ASD) closure
  • Cross clamp time ≤ 90 min
  • Cardiopulmonary bypass time ≤ 120 min.

Exclusion Criteria:

  • Poor left ventricular function with intra-aortic balloon pump support
  • Recent myocardial infarction (last seven days)
  • Combined procedure (i.e., CABG + other heart/vascular procedure)
  • Emergency surgery, and Redo surgery,Hepatic or renal failure, creatinine >1.5 -History of neurological disorders or convulsions

Sites / Locations

  • Fayoum University hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Active Comparator

Placebo Comparator

Arm Label

Group (K)

Group (D)

Group (C)

Arm Description

Group (K): (n=30) will receive ketamine infusion 1-2 μg/kg/min (0.12 mg/kg/h) titrated to desired level of sedation.

Group (D): (n=30) will receive Dexmedetomidine infusion 0.1- 0.2 μg/kg/hour titrated to desired level of sedation.

Group (C): (n=30) will receive fentanyl only.

Outcomes

Primary Outcome Measures

The total postoperative fentanyl consumption (μg)
the total doses of postoperative fentanyl consumption in (μg)

Secondary Outcome Measures

Duration of mechanical ventilation
Duration of mechanical ventilation (day)

Full Information

First Posted
June 29, 2022
Last Updated
May 23, 2023
Sponsor
Fayoum University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT05474183
Brief Title
The Role of Ketamine and Dexmedetomidine in Opioid-Sparing Analgesia
Official Title
The Role of Ketamine and Dexmedetomidine in Opioid-Sparing Analgesia and Sedation in Adult Patients After Cardiac Surgery. A Randomized Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Completed
Study Start Date
August 5, 2022 (Actual)
Primary Completion Date
May 10, 2023 (Actual)
Study Completion Date
May 20, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Fayoum University Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Optimal multimodal opioid-sparing analgesic technique is considered as one of the most important Enhanced recovery pathways (ERPs) or enhanced recovery after surgery (ERAS) interventions that mitigate the undesirable effects of surgical stress response. Implementation of ERP has been shown to reduce postoperative complications and shorten the hospital LOS.
Detailed Description
In this study, the investigator hypothesizes that by using continuous infusion of ketamine or dexmedetomidine in addition to NSAIDs, the investigator can reduce or completely eliminate opioid use in adult patients after cardiac surgery. The anesthesia technique was composed of the following 10 steps: Premedication with oral Pregabalin 75 mg the night before surgery; For induction and maintenance of anesthesia: - Midazolam 0.02- 0.05 mg/kg bolus, -Fentanyl (cumulative dose 5-15 μg/kg), followed by continuousInfusion of Fentanyl; 2-3 μg/kg /h as a maintenance dose, Rocuronium: (0.6-1.0 mg/kg - intubation dose, followed by continuous Infusion of Rocuronium; 0.075-0.15 mg/kg/h as a maintenance dose, and Sevoflurane in a dose of 0.8-1.0 (MAC). Ventilation: Lung protective ventilation (Vt 6 ml/kg predicted body weight, + PEEP 5, + FiO2 60%), and we conducted a recruitment maneuver in order to prevent atelectasis. Monitoring: Routine monitors (ECG, SpO2, arterial line inserted using local anesthesia for pressure monitor and repeated ABG, Central line inserted after induction of anesthesia for monitoring CVP, ETCO2, core temperature through urinary catheter, and Activated Clotting Time (ACT) for monitoring of coagulation). Cerebral oximetry, and Bispectral Index (BIS) as an indicator of depth anesthesia was kept between 40 and 60. (5) Cardiopulmonary Bypass (CPB): Goal directed perfusion maintaining MAP ≥ 60, using Phenylephrine and Norepinephrine infusion. Additional propofol infusion (25 - 50µg/kg/min) was administered during CPB to maintain BIS between 40 and 60. Smooth conduct of CPB, with Mild hypothermia (28°C 32°C). Rewarming at the end of the procedure, Goal postop temperature >36 °C. (6) Perioperative Glycemic Control: Insulin infusion, and the perioperative Goal glucose ≤ 150 - 180. (7)Perioperative hemoglobin concentration: Goal hemoglobin transfusion trigger: 7.5 regardless of patient Age and Comorbidity. (8) Protamine: Post CPB protamine (heparin reversal) given up to the full dose (5 mg/kg after test dose) to return to baseline ACT. (9) Multimodal analgesia: In addition to continuous infusion of Fentanyl, at the end of the surgery, Paracetamol: 1 gm IV infusion over 15 min was administered with the sternum closure, and Surgical Incision Field Block using 30 ml of Bupivacaine 0.5% just before dressing. The patient will then be transferred intubated to Surgical ICU (SICU). (10) In SICU: Postoperative analgesia will be carried out for all groups. All patients will receive IV fentanyl via patient-controlled analgesia (PCA) with (10 µg.mL-1, with a bolus of 15 µg, and lockout 10 minutes, maximum cumulative dose of 90µ.hr-1 and no background dose). Before extubation, analgesia will be given as nurse-controlled analgesia (NCA) with the same regimen, depending on the sudden rise in HR or MABP ≥20% of the baseline. The total of 24 h. opioid consumption will be recorded. At this step, and for opioid-sparing analgesia and sedation, using the sealed envelope technique, patients will be randomly divided into three groups: Group (K): (n=30) will receive ketamine infusion of 1-2 μg/kg/min (0.12 mg/kg/h) titrated to the desired level of sedation. Group (D): (n=30) will receive Dexmedetomidine infusion 0.1- 0.2 μg/kg/hour titrated to desired level of sedation. Group (C): (n=30) will receive fentanyl only. All hemodynamic monitors used intraoperatively are continued in SICU, and in addition, the following parameters are used to monitor the level of analgesia and sedation -During mechanical ventilation: Richmond Agitation-Sedation Scale

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ketamine-Induced Mood Disorder
Keywords
ketamine, dexmedetomidine, Analgesia, Cardiac Surgery, Sedation

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
90 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Group (K)
Arm Type
Active Comparator
Arm Description
Group (K): (n=30) will receive ketamine infusion 1-2 μg/kg/min (0.12 mg/kg/h) titrated to desired level of sedation.
Arm Title
Group (D)
Arm Type
Active Comparator
Arm Description
Group (D): (n=30) will receive Dexmedetomidine infusion 0.1- 0.2 μg/kg/hour titrated to desired level of sedation.
Arm Title
Group (C)
Arm Type
Placebo Comparator
Arm Description
Group (C): (n=30) will receive fentanyl only.
Intervention Type
Drug
Intervention Name(s)
Ketamine
Other Intervention Name(s)
dexmedetomidine
Intervention Description
drug
Primary Outcome Measure Information:
Title
The total postoperative fentanyl consumption (μg)
Description
the total doses of postoperative fentanyl consumption in (μg)
Time Frame
the first 48 hours postoperative
Secondary Outcome Measure Information:
Title
Duration of mechanical ventilation
Description
Duration of mechanical ventilation (day)
Time Frame
the first 48 hours postoperative

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Age 18 - 65 years Ejection fraction (EF) > 35% Elective isolated CABG Valve surgery, Atrial septal defect (ASD) closure Cross clamp time ≤ 90 min Cardiopulmonary bypass time ≤ 120 min. Exclusion Criteria: Poor left ventricular function with intra-aortic balloon pump support Recent myocardial infarction (last seven days) Combined procedure (i.e., CABG + other heart/vascular procedure) Emergency surgery, and Redo surgery,Hepatic or renal failure, creatinine >1.5 -History of neurological disorders or convulsions
Facility Information:
Facility Name
Fayoum University hospital
City
Fayoum
State/Province
Faiyum Governorate
ZIP/Postal Code
63514
Country
Egypt

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
no plane
Citations:
PubMed Identifier
29026331
Citation
Gan TJ. Poorly controlled postoperative pain: prevalence, consequences, and prevention. J Pain Res. 2017 Sep 25;10:2287-2298. doi: 10.2147/JPR.S144066. eCollection 2017.
Results Reference
background
PubMed Identifier
27908839
Citation
Chapman CR, Vierck CJ. The Transition of Acute Postoperative Pain to Chronic Pain: An Integrative Overview of Research on Mechanisms. J Pain. 2017 Apr;18(4):359.e1-359.e38. doi: 10.1016/j.jpain.2016.11.004. Epub 2016 Nov 28.
Results Reference
background

Learn more about this trial

The Role of Ketamine and Dexmedetomidine in Opioid-Sparing Analgesia

We'll reach out to this number within 24 hrs